An Open Label, Randomized, Controlled Clinical Study to Evaluate the Therapeutic Efficacy of a Specific Unani Formulation in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) - NI

Jamia Hamdard0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Patients of grade 1 and grade 2 Fatty Liver (up-to 290 db/m in QUS/ Fibroscan)
•2. Patients willing to participate and ready to sign the written informed consent.
•3. Patients diagnosed as having fatty liver based on the ultrasonography report.
•4. Patients with/ without clinical signs and symptoms.

•1. Patients having documented fatty liver grade 3 or above.
•2. Use of alcohol or any other drug abuse.
•3. Patients diagnosed with any coexisting liver disease.
•4. Pregnant and lactating women.
•5. Patients suffering with Hypertension, CKD, CAD, CLD or uncontrolled DM, Hypothyroidism.
•6. Patient having immune-compromised status.
•7. Patient using lipid lowering drugs or dietary supplements within the last 3 weeks.
•8. Oral contraceptives & corticosteroids.
•9. Neurological disorders like epilepsy or psychiatric disorders.
•10. Patient having history of Pancreatitis.
•11. Acute hepatitis with raised serum bilirubin.

发起方